Description

SITARA M 5/500 MG

Indications

SITARA M 5/500 MG is a pharmaceutical formulation that combines two active ingredients: Metformin and Sitagliptin. It is primarily indicated for the management of type 2 diabetes mellitus in adults. This combination medication is designed to improve glycemic control when diet and exercise alone are insufficient. SITARA M is particularly beneficial for patients who may require dual therapy to achieve optimal blood sugar levels.

Mechanism of Action

The efficacy of SITARA M 5/500 MG stems from the synergistic action of its two components. Metformin, a biguanide, primarily works by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and enhancing insulin sensitivity in peripheral tissues, which leads to improved glucose uptake and utilization. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin effect by preventing the degradation of incretin hormones, which increases insulin secretion in response to meals and decreases glucagon secretion, thereby lowering blood glucose levels. Together, these mechanisms provide a comprehensive approach to managing hyperglycemia in individuals with type 2 diabetes.

Pharmacological Properties

SITARA M 5/500 MG exhibits pharmacokinetic properties that are essential for its therapeutic effectiveness. Metformin is absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 2 to 3 hours after oral administration. It has a half-life of about 6 hours and is primarily excreted unchanged by the kidneys. Sitagliptin, on the other hand, is also well absorbed, reaching peak plasma concentrations within 1 to 4 hours. It has a longer half-life of approximately 12.4 hours and is primarily eliminated through renal excretion. The combination of these two agents allows for a sustained action that helps maintain blood glucose levels within the target range throughout the day.

Contraindications

SITARA M 5/500 MG is contraindicated in patients with a known hypersensitivity to either Metformin or Sitagliptin or any of the excipients in the formulation. It is also contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with a history of pancreatitis. Caution is advised in patients with liver dysfunction, as this may increase the risk of lactic acidosis associated with Metformin.

Side Effects

Common side effects associated with SITARA M 5/500 MG include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, particularly during the initial stages of treatment. Other potential side effects may include headache, dizziness, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis, pancreatitis, and hypersensitivity reactions. Patients should be monitored for any signs of these adverse effects, and appropriate management should be initiated as necessary.

Dosage and Administration

The recommended starting dose of SITARA M 5/500 MG is typically one tablet taken orally once daily, with or without food. The dosage may be adjusted based on individual patient response and tolerability, with a maximum dose not exceeding 100 mg of Sitagliptin and 2000 mg of Metformin per day. It is essential for patients to adhere to their prescribed dosage and to consult their healthcare provider before making any changes to their medication regimen. Regular monitoring of blood glucose levels is recommended to assess the effectiveness of the treatment.

Interactions

SITARA M 5/500 MG may interact with other medications, potentially altering their effects or increasing the risk of adverse reactions. Concomitant use of diuretics, corticosteroids, and other medications that may affect renal function can increase the risk of lactic acidosis. Additionally, certain drugs that affect the metabolism of Sitagliptin, such as strong CYP3A4 inhibitors, may lead to elevated levels of Sitagliptin in the bloodstream. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Prior to initiating treatment with SITARA M 5/500 MG, a thorough medical history and assessment of renal function should be conducted. Patients with a history of cardiovascular disease, liver disease, or those who are elderly may require closer monitoring due to the increased risk of adverse effects. It is also crucial to educate patients about the signs and symptoms of lactic acidosis, such as unusual muscle pain, difficulty breathing, or abdominal discomfort, and to seek immediate medical attention if these symptoms occur. Patients should be advised to maintain a balanced diet and engage in regular physical activity as part of their diabetes management plan.

Clinical Studies

Clinical studies evaluating the efficacy and safety of SITARA M 5/500 MG have demonstrated significant improvements in glycemic control among patients with type 2 diabetes. In randomized controlled trials, patients receiving the combination therapy showed a greater reduction in HbA1c levels compared to those receiving monotherapy with either Metformin or Sitagliptin alone. Furthermore, the combination therapy was well tolerated, with a safety profile consistent with the individual components. These findings support the use of SITARA M as an effective option for patients requiring dual therapy for better glycemic management.

Conclusion

SITARA M 5/500 MG represents a valuable therapeutic option for the management of type 2 diabetes mellitus. By combining the actions of Metformin and Sitagliptin, this medication addresses multiple pathways involved in glucose regulation, offering enhanced glycemic control for patients. While generally well tolerated, it is essential for patients to be aware of potential side effects and interactions, as well as the importance of adhering to their prescribed treatment regimen. Ongoing monitoring and communication with healthcare providers are crucial to achieving optimal outcomes in diabetes management.